LEARNING OBJECTIVES

• Review currently approved CAR T-cell therapies for liquid malignancies.
• Understand data, goals of combination, and review ongoing strategies to utilize approved lymphoma therapies in conjunction with approved CAR T-cell therapies for enhanced CAR T-cell efficacy.
• Provide a snapshot of upcoming novel engineering strategies for the next generation of investigational CAR T-cell products for lymphoma.

Session date: 
03/31/2025 - 12:00pm to 1:00pm CDT
Add to calendar: 
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation

Please login or create an account to proceed.
Speaker Name: 
Eli Darnell, MD